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A B S T R A C T
Background: Raclopride is a selective antagonist of the dopamine D2 receptor. It is one of the most frequently
used in vivo D2 tracers (at low doses) for assessing drug-induced receptor occupancy (RO) in animals and hu-
mans. It is also commonly used as a pharmacological blocker (at high doses) to occupy the available D2 receptors
and antagonize the action of dopamine or drugs on D2 in preclinical studies. The aims of this study were to
comprehensively evaluate its pharmacokinetic (PK) profiles in different brain compartments and to establish a
PK-RO model that could predict the brain distribution and RO of raclopride in the freely moving rat using a
LC−MS based approach.
Methods: Rats (n = 24) received a 10-min IV infusion of non-radiolabeled raclopride (1.61 μmol/kg, i.e.
0.56 mg/kg). Plasma and the brain tissues of striatum (with high density of D2 receptors) and cerebellum (with
negligible amount of D2 receptors) were collected. Additional microdialysis experiments were performed in
some rats (n = 7) to measure the free drug concentration in the extracellular fluid of the striatum and cere-
bellum. Raclopride concentrations in all samples were analyzed by LC−MS. A population PK-RO model was
constructed in NONMEM to describe the concentration-time profiles in the unbound plasma, brain extracellular
fluid and brain tissue compartments and to estimate the RO based on raclopride-D2 receptor binding kinetics.
Results: In plasma raclopride showed a rapid distribution phase followed by a slower elimination phase. The
striatum tissue concentrations were consistently higher than that of cerebellum tissue throughout the whole
experimental period (10−h) due to higher non-specific tissue binding and D2 receptor binding in the striatum.
Model-based simulations accurately predicted the literature data on rat plasma PK, brain tissue PK and D2 RO at
different time points after intravenous or subcutaneous administration of raclopride at tracer dose (RO< 10%),
sub-pharmacological dose (RO 10%−30%) and pharmacological dose (RO> 30%).
Conclusion: For the first time a predictive model that could describe the quantitative in vivo relationship between
dose, PK and D2 RO of raclopride in non-anesthetized rat was established. The PK-RO model could facilitate the
selection of optimal dose and dosing time when raclopride is used as tracer or as pharmacological blocker in
various rat studies. The LC−MS based approach, which doses and quantifies a non-radiolabeled tracer, could be
useful in evaluating the systemic disposition and brain kinetics of tracers.
1. Introduction
Raclopride, a selective dopamine D2 receptor antagonist, is one of
the most widely used tracers for the in vivo investigations of D2 receptor
in animals and humans. In the first reported application of raclopride
(Köhler et al., 1985), rats received an intravenous (IV) injection of
radiolabeled [3H]-raclopride at a low, tracer dose (2.82 nmol/kg) be-
fore the administration of D2 receptor agonists (e.g. drugs for
Parkinson's disease) or antagonists (e.g. drugs for schizophrenic dis-
orders). The displacement of [3H]-raclopride from the postmortem
striatum tissue, the dopaminergic region with high density of D2 re-
ceptors, by the drug was measured as receptor occupancy (RO). With
the advancement of imaging techniques, raclopride was also applied
intravenously to living rats (Hume et al., 1992) and humans (Farde
et al., 1986) as radiolabeled [11C]-raclopride for imaging D2 receptors
by positron emission tomography (PET).
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Raclopride is also used in higher doses for neurological and beha-
vioral studies in rats. In this case raclopride acts as a D2 blocker to
partially or completely occupy the available receptors and prevent the
potential interactions between the D2 receptors and the studied drug
(and endogenous dopamine), which would verify the role of D2 re-
ceptors in the functional outcomes of the interventions. Therefore, the
dose of raclopride in rat could range from very low (as tracer) to very
high (as pharmacological blocker) depending on the purpose, and
choosing an accurate dose is of utmost importance.
While raclopride has been used in rat studies for three decades,
surprisingly many crucial aspects of its pharmacokinetics (PK) have
remained unknown. Although there were a few studies on the PK of IV
raclopride in non-anesthetized rat (Table 1), the utility of those PK data
was hampered by the study design employed. First, in one study, for
some studies radiolabeled [3H]-raclopride was administered and the
total radioactivity in plasma or brain tissue was measured (Köhler et al.,
1985). Since raclopride is rapidly metabolized, soon after IV adminis-
tration the parent raclopride only accounted for a small portion of the
total radioactivity in plasma (< 60% at 20 min) (Patel et al., 2008).
Therefore, the radioactivity-time profile could not be translated into the
raclopride concentration-time profile. Second, in two other studies,
plasma and brain tissue PK profiles were not simultaneously reported
(Barth et al., 2006; Suresh et al., 2011). Third, there is no report on the
free drug concentration in brain extracellular fluid (ECF), which is the
driving force for binding to membrane receptors (de Lange, 2013).
To determine the optimal raclopride dose for a particular study, a
mathematical model that could link the dose to PK profiles in relevant
body compartments and brain D2 RO is needed. A few compartmental
PK models have been developed, but all of them were derived from the
radioactivity data of PET imaging studies, which were performed in
anesthetized rats that received IV [11C]-raclopride (Hume et al., 1992;
Morris and Yoder, 2007). The predictive power of these models has also
not been validated with external data. In addition to the aforemen-
tioned problem related to radioactive metabolites, the total radio-
activity measured also could not make distinction between brain ECF
concentration and brain tissue cell concentration. Moreover, the an-
esthesia procedures have profound impact on the PK and D2 RO of
raclopride. Obviously, non-anesthetized rats are preferred in most
neurological studies, especially for those intended to link the drug PK
profile to the behavioral and neurochemical changes (Wong and Zuo,
2013). Furthermore, striatum D2 RO should be incorporated in the
model since it has been demonstrated that the pharmacological effect of
raclopride could be predicted from its RO (Wadenberg et al., 2000).
Therefore, there is a need for a new PK-RO model that is derived from
data of non-anesthetized rats.
Recently, it is proposed that in small animals the in vivo brain ki-
netics of a tracer could be evaluated with a LC−MS based approach,
which doses and quantifies a non-radiolabeled tracer instead of a
radiolabeled one (Joshi et al., 2014). The main advantages are the
avoidance of the physiological and technical concerns associated with
the use of anesthesia and radiotracer in the PET imaging approach,
which could facilitate the development of new tracers (details in Dis-
cussion Sections 4.2 and 4.3).
The aim of the current study is to develop a model that could predict
the PK profiles of raclopride in plasma and brain and the corresponding D2
RO in the striatum. To that end, with a LC−MS based approach, we first
performed an in vivo study to simultaneously measure raclopride con-
centrations in plasma, brain ECF (with microdialysis technique) and brain
tissue in non-anesthetized, freely moving rats receiving non-radiolabeled
raclopride via IV administration. The data would be used to construct a
PK-RO model with the population approach that took into account the
inter-individual variability between the studied rats. The developed model
would be validated by comparing the simulated PK and D2 RO values to
those reported in previous literature (Table 1). The developed PK-RO
model is expected to become a useful tool to guide researchers on the
optimal dosing of raclopride in different types of studies.Ta
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2. Methods
2.1. Animals
Animal experiments were performed in accordance with the Dutch
Law of Animal Experimentation. The study protocol (DEC14051) was
approved by the Animal Ethics Committee in Leiden. Male Wistar rats
(n = 24, Charles River, The Netherlands) were housed in groups for
6–9 days until surgery (Animal Facilities Gorlaeus Laboratories, Leiden,
The Netherlands), under standard environmental conditions with ad
libitum access to food (Laboratory chow, Hope Farms, Woerden, The
Netherlands) and acidified water. Artificial daylight was provided from
7:30 AM to 7:30 PM. The average weight of the rat was
0.267 ± 0.008 kg on the day of pharmacokinetic experiment. The
general setting of the animal experiment was adapted from van den
Brink et al. (2017), and the details were outlined below.
2.2. Surgery
The surgery was executed as described previously (Westerhout
et al., 2012) with small modifications. To summarize, during all sur-
gical procedures the rats were kept under 2% isoflurane anesthesia.
Cannulas were placed in the femoral vein for the administration of
raclopride and in the femoral artery for blood sampling. In seven rats
microdialysis would be performed for serial sampling of brain ECF. In
these rats, two microdialysis guides (CMA 12 Guide Cannula, Aurora
Borealis Control BV, Schoonebeek, the Netherlands) were embedded in
the brain striatum (AP −1.0; L 3.2; V −3.5 mm relative to bregma)
and cerebellum (AP −2.51; L 2.04; V −3.34 mm, at an angle of 25°
from the dorsoventral axis (toward anterior) and 11° lateral from the
anteroposterior axis relative to lambda). The rats were given 7 days to
recover from surgery in Makrolon type 3 cages. One day before the
experiment, the microdialysis guides were substituted by the micro-
dialysis probes (CMA 12 Elite Polyarylethersulfone, 4 mm membrane,
cut-off 20 kDA, Aurora Borealis Control BV, Schoonebeek, the Nether-
lands).
2.3. Pharmacokinetic experiment
The experimental setting of the current study was summarized in
Table 1. All experiments started between 8:00 AM and 9:00 AM. Ra-
clopride infusion solution was prepared by dissolving non-radiolabeled
S(−)-raclopride (+)-tartrate (Sigma-Aldrich, St Louis, USA) in saline.
Rats received 10-min IV infusion of raclopride 0.56 mg/kg (i.e.
1612 nmol/kg) at the start of experiment (t = 0 min). Microdialysate
perfusion buffer was prepared as described previously (Stevens et al.,
2009), and 60 min before the experiment the perfusion was started
using a flow rate of 1 μL/min until the end of experiment. Microdialysis
samples were collected every 20 min, and those with a deviated flow
rate of> 10% were discarded. Blood samples of 200 μL were collected
at serial time points in heparin-coated plastic tubes. After each sam-
pling 200 μL saline was injected to compensate the fluid loss. The
samples were centrifuged (2300 ×g, 10 min) for separation of plasma.
At a predefined time point after raclopride administration, the rat was
euthanized with an overdose of pentobarbital sodium (ASTfarma B.V.,
The Netherlands) via the venous cannula. Cerebrospinal fluid was col-
lected with cisternal puncture before transcardial perfusion with
50 mM phosphate buffer (pH 7.4). The cerebrospinal fluid sample was
visually inspected for blood contamination (discarded if contaminated),
briefly centrifuged (16,100 ×g, 1 min), and the bottom portion
(≈20 μL) was removed since it might contain some large molecules
such as blood cells (if any). The whole brain was removed, and the
cerebellum and striatum were dissected and weighed. All samples were
stored at 4 °C during the experiment and at −80 °C after the experi-
ment until analysis.
2.4. Sample analysis
The concentrations of raclopride in the plasma, brain tissue and
microdialysate were measured using the liquid-liquid extraction and
LC-MS/MS assay methods previously developed and validated in our
laboratory (Stevens et al., 2010) with small modifications. In short,
formic acid instead of trifluoroacetic acid was added to the solvents of
on-line solid phase extraction and liquid chromatography to improve
the column lifetime while maintaining the same performance in peak
shape and resolution. Moreover, raclopride-d5 (Toronto Research
Chemicals Inc., Toronto, Canada) was used as the internal standard.
Cerebrospinal fluid was analyzed in the same manner as that of mi-
crodialysate. The lower limits of quantification of plasma, brain tissue,
microdialysate and cerebrospinal fluid were 3.6 nM, 2.8 nM, 1 nM and
1 nM, respectively. Samples with concentrations lower than the lower
limit of quantification were excluded from the PK-RO modeling.
The in vivo recovery of the microdialysis probe was determined by in
vivo loss experiments (Yamamoto et al., 2017) by perfusing the probe
with raclopride at 58, 288, and 864 nM. The recoveries of striatum
probe (28 ± 4%) and cerebellum probe (28 ± 4%) were found to be
the same. Therefore, the microdialysate concentrations in both tissues
were corrected for 28% to obtain the brain ECF concentrations. The
total plasma concentrations were corrected for the fraction unbound of
36.7% (Summerfield et al., 2008) to obtain the unbound plasma con-
centration.
2.5. Development and evaluation of the population PK-RO model
The population PK-RO analysis was performed using a non-linear
mixed effects modeling approach, which estimates the typical (mean)
value of model parameters as well as their inter-individual variances. In
NONMEM® (version 7.3.0, ICON), subroutine ADVAN6 and first-order
conditional estimation with interaction (FOCE-I) method were used to
estimate the model parameters. Exponential error models were utilized
to estimate the inter-individual variability in parameters. For residual
unexplained variability, proportional and additive plus proportional
models were tested. The stability of the model was assessed on the basis
of goodness of fit plots and successful termination with estimates of
fixed effects not close to a boundary. The robustness of the final model
was assessed by bootstrap. Predictive checks were also performed by
overlaying the model-based simulations and the observed concentra-
tions to evaluate the predictability of the model (Bosch et al., 2016).
The model structure is shown in Fig. 1. The differential equations are
listed in Table 2.
Regarding the raclopride-D2 binding in striatum, the association
rate kon at 0.049 nM−1 min−1 and the dissociation rate koff at
0.078 min−1 were used as initial estimates, which corresponded to an
affinity Kd (= koff / kon) of 1.6 nM. These values were obtained from in
vitro raclopride binding kinetics assays on D2 receptors expressed on
CHO-cells (Packeu et al., 2010), and similar values were also observed
in in vitro assays with rat striatum homogenate (Hall et al., 1988). The
concentration of total D2 binding site in striatum (Bmax) was fixed to
25 nM (Cumming, 2011; Hall et al., 1988).
2.6. Simulation in Berkeley Madonna and comparison with literature data
Simulations were performed using the differential equation solver in
the Berkeley Madonna software (Version 8.3.18), with the fourth-order
Runge-Kutta integration algorithm. To simulate the drug concentrations
and D2 RO outcomes after IV raclopride dosing, the estimated para-
meters of the structural model (Table 3) were used while the vari-
abilities (inter-individual variability and residual unexplained varia-
bility) were not incorporated in the simulation. Allometric scaling of
systemic drug disposition was necessary since in previous studies the
body weights of the rats differed widely (Table 1). The systemic
clearance from central distribution compartment (V1) of the rat in a
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previous study (CLnew) was derived from the systemic clearance in the
current PK-RO model (CLoriginal, i.e. 0.0426 L/min), such that
CLnew = CLoriginal × (BWnew/BWoriginal)exp, where BWnew and BWoriginal
were the average body weights of the rats in that previous study and in
the current study (0.267 kg), respectively. The central distribution
compartment (V1) and the two peripheral distribution compartments
(V8 and V9) were also scaled in the same way. The exponents (exp) for
clearance and distribution volumes were 0.75 and 1, respectively
(Knibbe et al., 2005). Allometric scaling was not performed for the
brain compartments since starting from the age of one month (body
weight around 0.08 kg) the volume of brain is already close to (around
90%) that of full adult (Mengler et al., 2014). To further simulate the
RO outcome after subcutaneous raclopride dosing, an absorption pro-
cess from the subcutaneous site to plasma was added to the differential
equations and was described by a first-order absorption rate. All si-
mulations were then compared to the observed data obtained from
previous studies (Table 1).
Plasma
unbound
Peripheral 1 Peripheral 2
1
8
Striatum
Extracellular fluid
Cerebellum
Extracellular fluid
2
3
Striatum
D2-bound6
Cerebellum
Non-specific binding
Striatum
Non-specific binding
kon
fu,brain(striatum)
fu,brain(cerebellum)
7
5
IV dose
9
koff
Q8
4
CL
Q9
Q7
Q5
Q2
Q3
Fig. 1. Schematic overview of the PK-RO model describing the
concentration-time profiles of raclopride in plasma and brain.
Table 2
Differential equations for the PK-RO model.
Compartment number and equation Explanation
1. d/dt (A1) =−K ∗ A1− K12 ∗ A1 + K21 ∗ A2− K13 ∗ A1 + K31 ∗ A3− K18 ∗ A1 + K81 ∗ A8− K19 ∗ A1 + K91 ∗ A9 + rate_in • Unbound plasma compartment
2. d/dt (A2) = K12 ∗ A1− K21 ∗ A2− K27 ∗ A2 + K72 ∗ A7 ∗ FUST− KON ∗ A2 / V2 ∗ (TotalAD2− A6) + KOFF ∗ A6 • Brain striatum extracellular fluid (ECF)
compartment [measured by
microdialysis]
3. d/dt (A3) = K13 ∗ A1− K31 ∗ A3− K35 ∗ A3 + K53 ∗ A5 ∗ FUCB • Brain cerebellum extracellular fluid
(ECF) compartment [measured by
microdialysis]
4. d/dt (A4) = A6 + A7 • Brain tissue striatum, total amount of
raclopride (D2-bound plus non-
specific tissue bound, i.e. A6 + A7)
[measured by total tissue
homogenate]
5. d/dt (A5) = K35 ∗ A3− K53 ∗ A5 ∗ FUCB • Brain tissue cerebellum, total amount
of raclopride (D2-bound plus non-
specific tissue bound; but negligible
amount of D2 receptor in cerebellum
assumed) [measured by total tissue
homogenate]
6. d/dt (A6) = KON ∗ A2/V2 ∗ (TotalAD2− A6)− KOFF ∗ A6 • Brain tissue striatum, amount of D2-
bound raclopride (A6: amount of D2-
raclopride complex)
7. d/dt (A7) = K27 ∗ A2− K72 ∗ A7 ∗ FUST • Brain tissue striatum, amount of non-
specific tissue bound raclopride
8. d/dt (A8) = K18 ∗ A1− K81 ∗ A8 • Peripheral compartment 1
9. d/dt (A9) = K19 ∗ A1− K91 ∗ A9 • Peripheral compartment 2
FUCB: fraction unbound in cerebellum tissue; FUST: fraction unbound in striatum tissue.
rate_in: rate of raclopride entrance into unbound plasma compartment (nmol min−1).
TotalAD2 = total amount of D2 receptor binding site in striatum tissue (nmol), i.e. total concentration of D2 receptor binding site in striatum (Bmax = 25 nM) × physiological volume of
striatum (0.0001 L) = 0.0025 nmol.
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3. Results
3.1. In vivo microdialysis study: characteristics of raclopride PK profiles
after IV dosing
The PK profiles in plasma, brain ECF and tissues after the 10-min IV
raclopride infusion are presented in Fig. 2. For the first 3 h, raclopride
showed a biphasic decline in plasma with a rapid distribution phase
(lasted for around 20 min after the infusion) and a slower elimination
phase. Indeed, our simulation suggested that 3 h after the dosing there
would be a third phase in which the plasma elimination rate became
even slower (Fig. 4). For brain ECF, the PK profiles in striatum and
cerebellum were similar, and both demonstrated monophasic elimina-
tion for the first 2.5 h. For brain tissues, the elimination of raclopride
was biphasic and the elimination rate became slower at time = 4 h.
Concentrations in striatum tissue were consistently higher than that of
cerebellum tissue throughout the whole experimental period (10-h) in
each studied rat. The concentration in cerebrospinal fluid was similar to
those in ECF (Supplementary Fig. 1).
3.2. Development of the PK-RO model
The model structure is shown in Fig. 1. Before incorporating the
brain compartments, we first developed a simple PK model that could
adequately describe the plasma PK profile. Adding one peripheral dis-
tribution compartment to the central compartment made it possible for
NONMEM to describe the plasma data in NONMEM, but the addition of
a second peripheral compartment was even better in terms of objective
function values. Further addition of peripheral compartments did not
significantly improve the model. In addition to an improvement in
objective function values, our simulation based on a PK model with two
peripheral compartments also adequately captured the tri-phasic PK
profile of non-radiolabeled raclopride observed in (Suresh et al., 2011)
(Fig. 4). Therefore, a PK model consisted of a central compartment and
two peripheral compartments was adopted. While the exact pharma-
cological mechanisms that give rise to two peripheral compartments
remain to be explored, it is possible that one peripheral compartment
(compartment 8) represents the body tissues that the lipophilic raclo-
pride has high affinity to but the blood perfusion to these tissues is poor
(e.g. lipophilic tissues such as fat tissue). This would manifest as a high
volume of distribution (high V8 of 1.24 L) but low clearance (low Q8 of
0.0035 L/min) as shown in Table 3. On the other hand, the other per-
ipheral compartment (compartment 9) might represent the body tissues
that the lipophilic raclopride has low affinity to but the blood perfusion
to these tissues is good.
Considering the complexity of the PK-RO model, certain constraints
had to be applied to the model to enhance the sensitivity of the model
to the remaining parameters and to reduce the uncertainty in their
estimation. The main constraints applied were (1) the clearance be-
tween brain ECF and brain cells (Q5 and Q7) was fixed at a high ar-
bitrary value, (2) certain PK parameters were fixed in the final PK-RO
model, and (3) kon was fixed at the value reported in in vitro binding
kinetics study and koff was estimated by the PK-RO model. The ratio-
nales behind these constraints are explained below in Section 3.2.
Raclopride can rapidly penetrate across the biological membranes.
In vitro studies suggest that for raclopride the entire process of phos-
pholipid membrane translocation (from drug adsorption to membrane
to drug release from membrane) could occur on a time scale of seconds
(Baciu et al., 2006; Casey et al., 2014). Therefore, a fast equilibrium
between brain ECF and brain cells was assumed, and the clearance
Table 3
Parameter estimates and bootstrap results for the raclopride PK-RO model.
Parameter Unit Parameter
estimate
RSE Bootstrap
mediana
CV
Structural model
CL L/min 0.0426 3.9% 0.0431 4.0%
V1 L 0.0255 15.9% 0.0269 20.9%
Q2 L/min 0.0281 13.9% 0.0266 30.0%
V2 L 0.405 14.1% 0.400 31.9%
Q3 L/min 0.0169 14.7% 0.0199 38.0%
V3 L 0.205 24.3% 0.218 49.7%
fu,brain
(striatum)
0.0970 6.1% 0.0965 8.0%
fu,brain
(cere-
bellum)
0.130 10.7% 0.128 11.4%
koff min−1 0.165 20.4% 0.161 35.7%
kon nM−1 min−1 0.049 (fixed) N.A. N.A.
Q5 L/min 0.06 (fixed) N.A. N.A.
V5 L 0.0002b (fixed) N.A. N.A.
V6 L 0.0001b (fixed) N.A. N.A.
Q7 L/min 0.06 (fixed) N.A. N.A.
V7 L 0.0001b (fixed) N.A. N.A.
Q8 L/min 0.0035 (fixed) N.A. N.A.
V8 L 1.24 (fixed) N.A. N.A.
Q9 L/min 0.0595 (fixed) N.A. N.A.
V9 L 0.146 (fixed) N.A. N.A.
Inter-individual variability (IIV)
IIV-CL 0.0321 29.3% 0.0308 45.1%
IIV-Q3 0.0504 (fixed) N.A. N.A.
IIV-V3 0.0648 (fixed) N.A. N.A.
IIV-Q9 0.128 (fixed) N.A. N.A.
Proportional residual variability
Plasmac 0.0173
(4.0)c
24.9%
(22.4%)c
0.0164
(4.0)c
27.7%
(20.7%)c
Striatum ECF 0.0572 19.2% 0.0527 28.0%
Cerebellum
ECF
0.0404 21.4% 0.0404 25.2%
Striatum tissue 0.0240 52.9% 0.0215 85.1%
Cerebellum
tissue
0.0880 37.2% 0.0796 40.5%
RSE = relative standard error. CV = coefficient of variation.
a Based on 157 bootstrap runs that minimized successfully.
b The volume of cerebellum tissue (V5) and striatum tissue (V6 and V7) was fixed to
the physiological volume (200 mg and 100 mg, approximately 0.0002 L and 0.0001 L,
respectively).
c Combined proportional and additive error was used for plasma compartment.
Fig. 2. PK profiles of raclopride in different compartments after IV raclopride dosing
(1613 nmol/kg). The curves are generated by local regression smoothing (LOESS). The
scatterplots for the data of each compartment are shown in Fig. 3A to E.
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between these two compartments (Q5 and Q7) was artificially fixed at a
high value. Sensitivity analysis suggested that the estimation of other
parameters was not sensitive to the value of Q5 and Q7 (unless Q5 and
Q7 were at unreasonably low values) (data not shown). Similar ap-
proach was also used in the modeling of intra-brain distribution of other
lipophilic drugs (Kozielska et al., 2012). The estimated unbound frac-
tion of raclopride in brain (fu,brain) was lower in striatum (0.097) than
that in cerebellum (0.13). With the in vitro brain slice method (Loryan
et al., 2013), the unbound volume of distribution of raclopride in
striatum and cortex was 11.2 and 9.8 mL per gram of brain tissue, re-
spectively (personal communication with Irena Loryan), which also
suggested a higher binding to the striatum tissue. Due to the complexity
of the PK-RO model, NONMEM was unable to give stable estimation on
the parameters of the peripheral compartments and some parameters
related to the inter-individual variability. Therefore, we estimated these
parameter with a PK model (without receptor binding), and the esti-
mated values were then fixed in the subsequent PK-RO model.
To model the binding of raclopride to D2 receptors, at first we tried
to estimate koff and kon simultaneously. However, during the NONMEM
iterations both koff and kon kept increasing monotonically without any
sign of convergence while the ratios of koff and kon maintained at
around 3.3 to 3.4 at each iteration. The model could not minimize
successfully, probably because that based on the available data
NONMEM could estimate Kd (i.e. koff/kon) but not individual koff and kon
values. We then tried fixing either the koff value or kon value to the
initial estimate (koff at 0.078 min−1 or kon at 0.049 nM−1 min−1, see
Section 2.5) and estimating the other. Both models could minimize
successfully. When koff was fixed at 0.078 min−1, the estimated kon was
0.0228 nM−1 min−1. On the other hand, when kon was fixed at
0.049 nM−1 min−1, the estimated koff was 0.165 min−1. Therefore,
both models gave an estimate of Kd at 3.4 nM. The two models gave
exactly the same estimates on all parameters (in both structural model
and the variabilities). Nevertheless, the precision of the estimates was
much higher when kon was fixed (RSE≤29% for all parameters, except
for residual variability in cerebellum tissue and striatum tissue, Table 3)
than that when koff was fixed (RSE 37%−350% for most parameters,
data not shown). Since the model with kon fixed and koff estimated gave
more a reliable estimation, this model was chosen for further evalua-
tions.
3.3. Evaluation of the PK-RO model
Visual predictive check was conducted by performing simulations of
the model for 200 times. The PK-RO model showed acceptable pre-
dictive performance, and the predictions overlaid the observed con-
centrations with good agreement in all the five compartments (Fig. 3).
Goodness-of-fit plots for observations versus predictions (population
predicted and individual predicted) are provided in the Supplementary
Fig. 2. No systematic differences between observations and predictions
were found, except that for striatum tissue and cerebellum tissue there
were a slight underestimation at the highest concentrations which were
measured soon after the completion of raclopride IV infusion
(t = 15 min). We tried to capture this unexpectedly high concentration
by adding a direct clearance between the plasma and brain tissue
compartment (Westerhout et al., 2013), but this did not improve the
prediction. In the current study, raclopride was administered as a 10-
min infusion (of diluted raclopride solution) instead of bolus injection
(of concentrated raclopride solution). The reasons were first to reduce
the potential changes in physiology and behavior (e.g. motor dysfunc-
tions such as catalepsy, (Wadenberg et al., 2000)) induced by this re-
latively high dose of raclopride and second to enhance the accuracy of
the amount of raclopride dosed. No brain tissue samples and only very
few brain ECF samples were collected before the completion of the 10-
min infusion. Therefore, the data did not have enough information to
provide a precise estimate of the initial (rapid) uptake from plasma to
brain ECF to brain tissue, and the initial binding from brain ECF to D2
receptors. This might also explain why NONMEM gave less precise es-
timations when it was asked to estimate the drug association rate to D2
(kon) as mentioned above.
The robustness of the model was assessed by bootstrap where the
original data were resampled. The model showed a high level of pre-
cision and the parameter estimates of the model were similar to that of
the bootstrap. Therefore, this model was chosen as the final model, and
it was used for subsequently simulations in Berkeley Madonna.
3.4. Prediction accuracy of the PK-RO model for IV raclopride
administration
The ultimate goal of this project was to predict the raclopride PK
and D2 RO in rats on the basis of our PK-RO model. The accuracy of the
prediction was evaluated by comparing the simulations generated in
Berkeley Madonna to those reported in previous literature (Table 1).
The model accurately predicted the plasma PK profiles after a tracer
dose (2.82 nmol/kg as [3H]-raclopride) and also a 1000-fold higher
dose (2880 nmol/kg as non-radiolabeled raclopride) (Fig. 4). It also
predicted the residue level of raclopride remaining in plasma one day
after the IV dose, and the two different elimination phases. After a low
dose of raclopride (6 nmol/kg), the model captured the trend of ra-
clopride concentration in cerebellum and striatum tissues, although it
underestimated the initial, highest concentration in striatum at
t = 5 min (Fig. 5), which was a limitation of the model as discussed
above. At this sub-pharmacological dose, the maximum D2 RO was
estimated to be 18%, which was consistent with the RO value suggested
by the investigators of that study (23%, (Barth et al., 2006)). Most
importantly, the model predicted well the striatum D2 RO values ob-
served after different IV doses (Köhler and Karlsson-Boethius, 1988)
(Fig. 6A), which strongly supported the validity of the model. The effect
of changing the koff value from 0.165 min−1 (while kon kept constant)
on RO was simulated. It could be observed that RO was sensitive to the
koff value, and a relatively small, two-fold change in would already
result in a considerable shift in the dose-RO curve (Fig. 6B). A simu-
lation example (based on the setting of rat D2 RO studies after IV ra-
clopride by (Köhler and Karlsson-Boethius, 1988)) is provided in Ber-
keley Madonna code in the Supplementary material.
3.5. Prediction accuracy of the PK-RO model for subcutaneous raclopride
administration
We tried to extend the application of the PK-RO model, which was
based on IV raclopride data, to the prediction in rats receiving sub-
cutaneous dosing. A first-order absorption rate was added to the model
to describe absorption process from the subcutaneous site to plasma.
Different values for this absorption rate were tested, and it was found
that the predicted RO-time profile increasingly approached the ob-
served RO-time profile (Fig. 7B) when the absorption rate kept in-
creasing up to 0.4 min−1, while a further increase in absorption rate
had no apparent impact on the simulated PK or RO profiles. Therefore,
the absorption rate was fixed at 0.4 min−1 for subsequent simulations.
The model not only predicted the RO after different subcutaneous doses
(Fig. 7A), it also predicted the RO at different time points, up to one day
after a subcutaneous dose (Fig. 7B). Under this fast absorption rate the
simulated plasma PK profile after subcutaneous dosing was similar to
that of IV raclopride, and the whole subcutaneous dose was completely
absorbed into plasma within a few minutes. Efficient subcutaneous
absorption is supported by in vivo observations. Even when sub-
cutaneous raclopride was administered to rat at much lower doses of
≤288 nmol/kg (20-fold lower compared with the 5760 nmol/kg by
(Wadenberg et al., 2000) in Fig. 7B), the D2-blockade-induced effects
on behavior (suppression of conditioned avoidance response) and
neurotransmitter levels (enhanced dopamine turnover) appeared very
soon after subcutaneous administration, before t = 20 min (Linnér
et al., 2002).
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4. Discussion
4.1. Novelty of the current study and utility of the developed PK-RO model
To our knowledge, this is the first population model developed for
raclopride and it could predict the PK and D2 RO after IV raclopride
dosing in rats. By combining the microdialysis technique (for brain ECF
measurement), LC−MS quantification and population modeling,
quantitative estimation of PK parameters of the non-radiolabeled drug
in all relevant plasma and brain compartments became feasible
(Yamamoto et al., 2017). Incorporating D2 receptor binding into the PK
model makes the model useful for dose selection since the pharmaco-
logical effects of raclopride is directly linked to and could be predicted
from its striatum RO (Wadenberg et al., 2000). Specifically, in rats
dosed with raclopride, suppression of conditional avoidance response (a
tentative behavioral marker suggesting an antipsychotic effect,
(Wadenberg, 2010)) occurs at a D2 RO around 70−75% while cata-
lepsy (a tentative behavioral marker suggesting motor dysfunction side
effect, (Wong and Zuo, 2013)) emerges only when D2 RO is> 80%
(Wadenberg et al., 2000). In addition to predicting the RO after IV
raclopride (Fig. 6), the model could be extended to predict the RO after
subcutaneous raclopride administration (Fig. 7). Nevertheless, the va-
lidity of this tentative subcutaneous model should be further verified
with plasma (and brain) PK data from rats receiving subcutaneous
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Fig. 3. Predictive check of the PK-RO model. Red lines represent 5% and 95% prediction quantile based on 200 simulated datasets. Dotted lines represent median of the simulated data.
Dots were observed data from the present study, at raclopride IV dose 1613 nmol/kg. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
Fig. 4. Prediction of unbound plasma PK after IV raclopride administration. Observed
data were from Suresh et al. at 2880 nmol/kg, and Köhler et al. at 2.82 nmol/kg.
Fig. 5. Prediction of brain tissue PK after IV raclopride. Observed data were from Barth
et al. at 6 nmol/kg. The corresponding RO was also simulated.
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dosing, which are currently not available in literature. An example of
Berkeley Madonna code for PK and D2 RO simulation is provided in the
Supplementary material. The advantages of the LC−MS based ap-
proach are further discussed in Sections 4.2 and 4.3.
4.2. Advantages of the “non-radiolabeled tracer with LC−MS
quantification” approach
When used as an in vivo tracer in animals, raclopride is usually
administered as radiolabeled [3H]-raclopride (or as [11C]-raclopride in
PET) with subsequent radioactivity measurement; however, an alter-
native approach that combines non-radiolabeled raclopride and
LC−MS quantification is gaining momentum in recent years. This is
first reported is by Barth and her colleagues (Barth et al., 2006; Chernet
et al., 2005), who used non-radiolabeled raclopride at a sub-pharma-
cological dose (IV 6 nmol/kg, estimated RO≈ 20%, Fig. 5) as a D2
tracer in rats, and the striatum and cerebellum tissue concentrations
were quantified by LC−MS. The striatum D2 RO values of eight anti-
psychotic drugs measured with this non-radiolabeled raclopride were
very comparable to those with the traditional [3H]-raclopride tracer
(tracer dose, 0.4 nmol/kg, IV). Since then this approach has been
adopted by other research groups, for instance in (Hutson et al., 2016;
Nirogi et al., 2013). Since most the drugs and tracers that act on the
central nervous system (including raclopride) are relatively lipophilic
and are extensively metabolized (Wong et al., 2012), LC−MS allows
unambiguous and simultaneous quantification of the drug, tracer and
their (active) metabolites in one single sample, which is not feasible
with radioactivity counting. Moreover, the limitations related to
radiochemical synthesis and radioactivity hazard could be avoided.
Furthermore, variation in specific activity of [11C]-raclopride, and
hence the amount of cold raclopride co-administered, could lead to
variation in the PET imaging outcomes such as binding potential (Hume
et al., 1992). In contrast, for non-radiolabeled tracer the amount of
raclopride administered should be more uniform and accurate. Last but
not least, the short 20-min decay half-life of [11C] restricts the collec-
tion of tracer kinetics data to only 1 h post-dose, while with non-radi-
olabeled tracers data could be collected over an extended period of time
(e.g. 10 h in the current study, and 24 h in (Suresh et al., 2011)), which
could provide a more complete dataset for subsequent data analysis and
modeling.
In summary, the LC−MS approach can facilitate the development
of new tracers and drugs, especially in the early development stages
such that the PK and RO time profiles of potential tracer/drug candi-
dates can already be characterized with the easily accessible LC−MS
before investing resources into radio-labeling and PET/SPECT imaging.
It is expected that such “non-radiolabeled tracer with LC−MS” ap-
proach will be increasingly adopted for both fundamental research and
drug development, and our PK-RO model will be useful for rat studies
that involve the administration of raclopride as D2 tracer.
Despite the aforementioned advantages of this LC−MS approach, it
should be emphasized that PET imaging remains the desired approach
in certain pharmacological studies. PET imaging is less invasive and
allows multiple measurements in the same animal, which is crucial for
longitudinal studies and evaluation of repeated drug or non-drug in-
terventions. Moreover, since radioactivity detection is more sensitive to
LC−MS quantification, the dose of raclopride tracer needed is lower
for radiolabeled raclopride, which would reduce the potential inter-
ferences to the outcomes due to the pharmacological actions of the
tracer itself. By analyzing the PET data with suitable modeling ap-
proach (considering for example the plasma input function, time-profile
of radio-metabolite, reference tissue model, etc.) (Dupont and Warwick,
2009), some of the shortcomings of small-animal PET imaging men-
tioned in Sections 4.2 and 4.3 could be compensated. Indeed, the
striatum binding potential obtained in [11C]-raclopride in non-
Fig. 6. Prediction of striatum D2 receptor occupancy after IV raclopride administration.
A) Dose-RO relationship. Observed data were from Köhler and Boethius, at t = 75 min. B)
The effect of changing koff from the original value of 0.165 min−1 (kon kept constant at
0.049 nM−1 min−1) on the simulated RO. The simulation setting was also based on the
study of from Köhler and Boethius, at t = 75 min.
Fig. 7. Prediction of striatum D2 receptor occupancy after subcutaneous raclopride ad-
ministration. A) Dose-RO relationship. Observed data were from Wadenberg et al. and
Marcus et al., at t = 60 min. B) RO-time profile. Observed data were from Wadenberg
et al., 2000, at 5760 nmol/kg.
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anesthetized humans was just comparable to those in anesthetized rats
and mice when the PET data was analyzed using the reference tissue
model (Kuntner, 2014), even though the metabolic conversion of [11C]-
raclopride to radio-metabolite is much slower in humans (Alexoff et al.,
1995) than in rodents (Hume et al., 1992; Patel et al., 2008).
4.3. Predicting raclopride PK and RO in anesthetized rats/restrained rats in
PET studies
It is important to mention that this PK-RO model was constructed
based on non-anesthetized, freely moving rats, and it might not be
applicable for the prediction of rats under anesthesia and/or restrain
which have profound impact on raclopride PK and RO. For conven-
tional PET imaging in rats or mice, anesthesia or complete restraint is
generally required to prevent motion artifact during imaging.
Isoflurane, an anesthetic commonly used in rodent PET imaging studies,
significantly increases the uptake of IV [3H]-raclopride to rat striatum
and cerebellum by 40% (McCormick et al., 2011). Ketamine plus xy-
lazine anesthesia also increases IV [11C]-raclopride rat brain uptake by
five-fold regardless of the brain region (Patel et al., 2008), which could
be partly due to the suppressive effect of ketamine/xylazine on systemic
clearance (Wong et al., 2014). Consequently, the IV raclopride dose
needed to occupy 50% of striatum D2 receptors in [11C]-raclopride PET
studies with anesthetized rats ranged from 6 nmol/kg (Schiffer et al.,
2005) to 9 nmol/kg (Opacka-Juffry et al., 1998) to 17 nmol/kg (Hume
et al., 1995). These were much lower than the required dose estimated
from the current study (Fig. 6) and a previous study (Köhler and
Karlsson-Boethius, 1988) with non-anesthetized rats (both around
100 nmol/kg), indicating that the effect of anesthesia on raclopride
kinetics is significant. Different anesthetics also differentially alter the
activity and dopamine turnover of dopaminergic neurons (Müller et al.,
2011), which would, in turn, alter the D2 RO of raclopride. On the other
hand, restraining a non-anesthetized rodent would decrease the binding
of [11C]-raclopride in striatum (Patel et al., 2008; Takuwa et al., 2015),
which is partly due to the immobility stress-induced dopamine released
and displacement of [11C]-raclopride.
Encouragingly, thanks to advance in mechanical and computational
engineering, raclopride PET imaging in rodents without the need of
anesthesia is in active development. Devices that allow [11C]-raclopride
brain imaging of non-anesthetized rodents that are freely walking with
minimal restrain have been developed (Schulz et al., 2011; Takuwa
et al., 2015). Besides PET imaging, an alternative approach would be
the use of intracerebral microprobe that is sensitive to beta emission
from [11C]-raclopride. A chronically implanted wireless pixelated beta-
microprobe was recently developed to measure the time-activity curves
of [11C]-raclopride in non-anesthetized, freely moving rats, and the
specific binding in striatum was significantly lower than those in iso-
flurane-anesthetized rats (Balasse et al., 2015). Therefore, imaging in
non-anesthetized rats is indeed feasible and in that case our PK-RO
model would be applicable.
4.4. Modeling raclopride PK and RO: current approach versus PET imaging
approach
In the current study, the in vivo data were analyzed by population
(nonlinear mixed effect) modeling to estimate PK (e.g. clearance be-
tween body compartments) and receptor binding parameters (Kd). This
modeling approach has several advantages (Liefaard et al., 2005). It is
possible to model all data from all rats simultaneously (e.g. data from
different studies, at different doses), resulting in better statistical power
for estimation of the parameters of interest that would otherwise be
difficult to quantify. Also, individuals with an incomplete dataset can
be included in the analysis. Finally, it is possible to estimate inter-in-
dividual variability of different structural parameters. The population
approach has been previously applied to the characterization of the
brain kinetics and RO of radiotracers from both small animal (Liefaard
et al., 2005) and human (Kågedal et al., 2012) PET data. Our current
study demonstrated that such approach could also be applied to non-
radiolabeled tracers.
Hume et al. (Hume et al., 1992) fitted their PET imaging data of a
single-dose [11C]-raclopride in anesthetized rats into a four-compart-
ment reference tissue model. The ratio between the rate constants of
raclopride uptake from the plasma compartment into striatum and
cerebellum ranged from 0.72 to 1.0. In our PK-RO model the rate
constants for striatum uptake (Q2/V2 = 0.069) and cerebellum uptake
(Q3/V3 = 0.082) gave a similar ratio of 0.84, again suggesting that the
uptake rate into striatum was slower than that into cerebellum.
Nevertheless, Hume et al. stated that the brain uptake values from in-
dividual rats varied considerably and the fitted rate constants had re-
latively large associated errors. Inter-individual variability was also
observed in the current study and some parameter estimates in our PK-
RO model showed certain degree of uncertainty (Table 3). It is worth
mentioning that the radio-metabolites of [11C]-raclopride does not
enter the rat brain tissue (Hume et al., 1992; Köhler et al., 1985) and
therefore only the plasma input function needed to be corrected for the
metabolites when modeling the PET data. For other radiotracers, it is
necessary to characterize the metabolites. If the contribution of the
radioactive metabolite at the tissue of interest cannot be neglected it
should be incorporated into the model (Dupont and Warwick, 2009).
In addition to the PET imaging technique, kinetics parameters of
[11C]-raclopride had also been estimated in anesthetized rats with the
beta-microprobe technique. With a multi-injection protocol, Mauger
et al. (Mauger et al., 2005) fitted the radioactivity data detected by the
intracerebral microprobe into a three-compartment model. The ratio
between the rate constants of raclopride uptake from into striatum and
cerebellum was 0.82, similar to those estimated by us and by (Hume
et al., 1992). Their estimated koff was 0.20 min−1, while ours was
0.17 min−1. Their estimated Bmax was 20 nM, which was close to the
value we used (25 nM). Therefore, while our approach (LC−MS based
approach with non-radiolabeled raclopride, data fitted into population
modeling) differed from those adopted by (Hume et al., 1992) and
(Mauger et al., 2005) (radioactivity based approach with [11C]-raclo-
pride, non-population modeling), comparable parameter estimates
were achieved, which supported the utility of our proposed approach.
4.5. Predicting raclopride PK and RO after repeated raclopride dosing
While the developed model could predict the PK and RO outcomes
after a single-dose of raclopride, whether it could also predict the
outcomes after repeated dosing remains to be explored. Ericson et al.
suggested that when raclopride was given repeatedly to rat, the plasma
concentration would increase with time, although no further informa-
tion was provided by the authors (Ericson et al., 1996). Self-inhibition
of metabolism via downregulation of CYP enzymes could be an ex-
planation. In rats, subchronic systemic administration of selective D2
antagonists such as raclopride and other similar benzamides sulpiride
and remoxipride could suppress the expression and activity of liver CYP
1A, 1B, 2B, 2C and 3A isozymes (Harkitis et al., 2015; Juřica et al.,
2011; Rane et al., 1996), while repeated intracerebral raclopride ad-
ministration increases CYP 2C activity (Sabová et al., 2013). In addition
to modifying systemic PK, chronic administration of raclopride (via
subcutaneous osmotic pump) also increases [3H]-raclopride binding
sites in rat striatum (See et al., 1990). In other words, certain PK (e.g.
systemic clearance) and D2-binding (Bmax, Kd) parameters need to be
changed in the repeated dosing setting.
4.6. The role of in vitro binding kinetics values in predicting in vivo D2 RO
The in vivo Kd value estimated by the current PK-RO model (3.4 nM)
is higher than the average Kd values from in vitro studies that measured
raclopride-D2 binding kinetics with rat striatum homogenate
(≈1.1 nM) (Cumming, 2011). If our estimated Kd is valid, then the
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lower affinity in vivo could be, at least partly, explained by the presence
of endogenous dopamine. The basal level of extra-synaptic dopamine in
rat striatum ECF is estimated to be 20−100 nM (Fisher et al., 1995;
Schiffer et al., 2005). Administration of D2 receptor antagonist such as
raclopride would increase dopamine turnover and dopamine release,
and after a high IV raclopride dose (D2 RO> 90%) dopamine con-
centration in rat striatum ECF would increase by 300% (Schiffer et al.,
2005). Dopamine concentration inside the synapse is expected to be
even higher, probably up to 100−200 nM (Laruelle, 2012). The in-
hibition constant of dopamine on [3H]-raclopride binding to high-affi-
nity state D2 receptors in rat striatum homogenate is around 20 nM
(Dewar et al., 1989; Hall et al., 1990), well below the dopamine con-
centration available and thus competitive inhibition is likely in vivo.
Indeed, among the commonly applied D2 antagonist tracers, raclopride
is suggested to be most sensitive to displacement by endogenous do-
pamine (Morris and Yoder, 2007). Dopamine not only competes with
raclopride for the D2 binding sites, but also induces long-lasting in-
ternalization of D2 receptors from plasma membrane into intracellular
environment. Since raclopride has a lower affinity for internalized re-
ceptors compared to receptor expressed at cell surface, this might also
contribute to the discrepancy between in vivo and in vitro Kd values
(Laruelle, 2012).
Binding kinetic parameters (Kd, koff, and kon) measured in in vitro
studies are also dependent on the experimental settings (de Witte et al.,
2016). For instance, in rat striatum tissue homogenate the Kd values of
[3H]-raclopride to D2 receptors maintained between 1.6 nM to 1.8 nM
when the incubation temperature increased from 15 °C to 30 °C; how-
ever, Kd raised to 3.0 nM when the temperature further increased to
37 °C (Hall et al., 1988). To accurately predict the RO, it is crucial to
adopt an integrative approach that combines well-designed (i.e. phy-
siologically relevant) in vitro binding studies and mathematical models
that describe the relevant in vivo processes (e.g. the effect of endogenous
ligand and receptor internalization) governing drug-receptor binding.
Interested readers are referred to recent reviews by (de Witte et al.,
2016) and (Schuetz et al., 2017) for details.
In addition to D2 receptor, raclopride also binds to D3 receptor in
vitro with comparable Kd (Seeman, 2011). Nevertheless, in striatum the
density of D3 receptor is at least several folds lower than that of D2
receptor, particularly for young rats (< 0.25 kg) (Hillefors et al., 1999;
Levant, 1998). Moreover, antipsychotics such as olanzapine, risper-
idone and clozapine, when administered to non-anesthetized rats at
clinically-relevant doses (D2 RO around 80%) occupy far smaller pro-
portion of D3 receptors (D3 RO< 40%) in vivo (McCormick et al.,
2013) than would be predicted by their in vitro affinities (i.e. compar-
able Kd at D2 and D3 (Seeman, 2011)). Therefore, raclopride binding to
D3 receptors should not have a quantitatively important contribution to
the total uptake measured in the striatum.
4.7. Summary
The present study, together with previous research, shows that ra-
clopride possesses most of the criteria required for a successful tracer
for drug targets in brain: for example, Bmax/Kd > 5–10,
fu,brain > 0.01–0.05, log P within 1 to 5, and rapid permeation across
blood-brain barrier without the involvement of active transport (Need
et al., 2017). In addition, the relatively fast kon and koff rates shorten the
time needed to reach equilibrium receptor binding, which is inversely
proportional to (kon × [raclopride concentration] + koff) (Guo et al.,
2015). It is expected that raclopride will continue to be one of the most
commonly used in vivo tracers for D2 investigations, and our PK-RO
model will be useful when designing these pharmacological studies.
The model could be used not just for selecting the optimal dose amount,
but also for selecting the optimal dosing method (for instance, the
duration of the IV infusion and the dosing time of raclopride relative to
the intervention being investigated, e.g. a drug challenge) in order to
achieve the desired D2 RO level at a certain time period.
5. Conclusion
A predictive model describing the quantitative relationship between
dose, PK and D2 RO of raclopride in non-anesthetized rat was estab-
lished. This PK-RO model could accurately predict the plasma PK, brain
tissue PK and striatum D2 RO after IV raclopride dosing. Further ex-
tension of this model for predicting D2 RO after subcutaneous raclo-
pride administration has been shown to be possible, although this
should be further validated with additional subcutaneous PK data. The
developed PK-RO model could facilitate the selection of optimal dose
and dosing time when raclopride is used as tracer or as pharmacological
intervention in various rat studies. This study also demonstrated that
the LC−MS based approach might complement the imaging-based
approach in evaluating the systemic disposition and brain kinetics of
tracers and facilitate the development of novel tracers.
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